Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. (November 2015)

• Record Type: Journal Article
• Authors: De Cobelli, Ottavio; Buonerba, Carlo; Terracciano, Daniela; Bottero, Danilo; Lucarelli, Giuseppe; Bove, Pierluigi; Altieri, Vincenzo; Coman, Ioman; Perdonà, Sisto; Facchini, Gaetano; Berretta, Massimiliano; Di Lorenzo, Giuseppe; Grieco, Paolo; Novellino, Ettore; Franco, Renato; Caraglia, Michele; Manini, Claudia; Mirone, Vincenzo; De Placido, Sabino; Sonpavde, Guru; Ferro, Matteo
• Is Part Of: Future oncology. Volume 11:Number 22(2015)
• Page Start: 3091
• Page End: 3098
• Publication Date: 2015-11
• Subjects: Gleason score -- prostate cancer -- urotensin II receptor; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.15.249
• Languages: English
• ISSNs: 1479-6694

Abstract

Aim: A higher Gleason score was associated with a lower tumor urotensin II receptor (UTII-R) expression in prostate cancer patients.Methods: A retrospective review of formalin-fixed paraffin-embedded tumor tissue derived from those who had prostatectomy and matching biopsy specimens was conducted at six Institutions. UTII-R expression was evaluated on biopsy by immunohistochemistry.Results: A total of 58 subjects undergoing radical prostatectomy were included. At multivariate analysis, low UTII-R expression was a significant predictor of Gleason upgrading, with an odds ratio of 10.3 (95% CI: 1.55–68.4), and of pathology upstaging, with an odds ratio of 11.1 (95% CI: 1.23–100.48).Conclusions: UTII-R expression on biopsy was associated with Gleason upgrading and pathology upstaging in prostate cancer patients.